2 Portal tract showing mild ductular proliferation accompanied by this prominent mixed inflammatory cell infiltrate. Group that presented less than 90 days after COVID-19 vaccination were collected. Their medical records were analysed and the following data were collected: age, sex, type of vaccine, latency (time in days from vaccination to detection of transaminase alterations), transaminase and bilirubin levels at diagnosis, liver biopsy, screening for liver disease (autoantibodies, immunoglobulins and viral serology) and HLA, as well as the treatment received and the response to it. A literature review of the subject was also carried out using the search terms Autoimmune hepatitis and Covid vaccine in PubMed, finding 20 articles that reported cases of post-vaccine autoimmune hepatitis. Table 1 shows the main characteristics of the cases described so far in the literature, in order to compare them with those of our patients. Table 1 LDN-212854 Post-vaccine autoimmune hepatitis cases reported in the literature. thead th rowspan=”1″ colspan=”1″ Study /th th rowspan=”1″ colspan=”1″ Sex and age /th th rowspan=”1″ colspan=”1″ Vaccine /th th rowspan=”1″ colspan=”1″ Latency (days) /th th rowspan=”1″ colspan=”1″ GOT/GPT at diagnosis (U/L) /th th rowspan=”1″ colspan=”1″ Bilirubin at diagnosis (mg/dl) /th th rowspan=”1″ colspan=”1″ Antibodies /th th rowspan=”1″ colspan=”1″ IgG /th th rowspan=”1″ colspan=”1″ Biopsy compatible with HAI /th /thead Bril et al [5]Female, 35Pfizer (1st dose)13754/20014,8ANA br / Ds-DNANYesLondo?o et al [6]Female, 41Moderna (2nd dose)7993/13122,3ANA, ASMA, SLA, LC1YesClayton-Chubb et al [7]Male, 36AstraZeneca (1st dose)26633/17741ANANYesTan et al [8]Female, 56Moderna (1st dose)351124/17016ANA, ASMAYesMcShane et al [9]Female, 71Moderna (unknown)4?/106712,1ASMAYesLodato et al [10]Female, 43Pfizer (1st LDN-212854 dose)1551/5217,5CNYesVuille-Lessard et al [11]Female, 76Moderna (1st dose)3811/5796,5ANA, ASMA, AAA, em p /em -ANCAYesRela et al [12]Female, 38AstraZeneca141101/10252,86ANAYesMale, 62AstraZeneca161361/109419,2CCYesTun et al [13]Male, 47Moderna (1st dose)3–/104819negativeYesPalla et al [14]Female, 40Pfizer (2nd dose)30×4 ULNCANAYesRocco et al [15]Female, 80Pfizer (2nd dose)71401/118610,5ANAYesGhielmetti M et al [16]Male, 63Moderna (1st dose)71127/103820,8ANA, atypical AMAYesAvci et al [17]Female, 61Pfizer (1st dose)30455/91311,8ANA, ASMAYesGarrido et al [18]Female, 65Moderna (1st dose)141056/10921,14ANAYesGoulas A et al [19]Female, 52Moderna (1st dose)14350/9369,06ANA, ASMAYesCamacho-Domnguez et al [20]Male, 79AstraZeneca (1st dose)272003/199411,9ANA, ASMAYesErard et al [21]Female, 80Pfizer (2nd dose)10583/5414,6ANAYesFemale, 73Moderna (1st dose)211163/102719,5ANAYesFemale, 68AstraZeneca (1st dose)202314/202944ANAYesFimiano et al. [22]Female, 63Pfizer (2nd dose)541625/177818,6Ac antitiroglobulinaYesGhorbani et al. [23]Male, 62Sinopharm (2nd dose)3435/7228CCYes Open in a separate window 3.?Results Since the start of vaccination, 5 cases of altered liver biochemistry less than 90 days after the first or second dose of the vaccine have been detected in our centre. One of the cases has already been presented in the journal Gastroenterology and Hepatology by Torrente et al. [3] and continues to be included alongside the various other new situations. Altogether, 4 from the sufferers had been females and 1 was a guy, using a median age group of 62 years. 3 sufferers received the vaccine from Pfizer and 2 from Astrazeneca. The median period in the last dosage of vaccine to recognition of liver organ function check (LFT) abnormalities was 19 times. No patient demonstrated evidence of liver organ failing at baseline or until treatment, although there is one case of serious severe hepatitis with a complete bilirubin degree of 14?mg/dl during follow-up that required hospitalisation. A liver organ disease screening research demonstrated autoimmunity (positive ANA) and raised IgG in every sufferers, with no various other alterations appealing. A liver organ biopsy was performed in 4 situations, and most of them had been appropriate for AIH. The histological adjustments are defined in further details in Desk 2 as well as the Batts-Ludwig program was utilized to define the fibrosis stage as well as the severe or persistent phenotype from the hepatitis. Desk 2 Clinical, histological and laboratory features of the entire situations discovered inside our centre. thead th rowspan=”1″ colspan=”1″ Individual amount /th th rowspan=”1″ colspan=”1″ 1 /th th rowspan=”1″ colspan=”1″ 2 /th th rowspan=”1″ colspan=”1″ 3 /th th rowspan=”1″ colspan=”1″ 4 /th th rowspan=”1″ colspan=”1″ 5 /th /thead SexFemaleMaleFemaleFemaleFemaleAge (years)4772627259ComorbiditiesHypothyroidism30?g/time alcohol intake, ischemic center diseaseCeliac diseaseNo comorbiditiesHypothyroidismVaccineAstrazeneca (1st dosage)Pfizer (2nd dosage)Astrazeneca (2nd dosage)Pfizer (2nd dosage)Pfizer (1st dosage)Latency (times)24464149ALT (U/L)3532486558661799AST (U/L)2412044985701292Total bilirubin (mg/dl)0.412.32.52.31.3IgG (mg/dl)20161670168419161978Autoantibodies testedANA+ 1/320 (AC-21 Cytoplasmic reticular/AMA) br / AMA (?) LKM LDN-212854 (?) ASMA (?) M2-3E (?) Sp-100 (?) gp-210 (?) LKM1 (?) LC1 (?) SLA/LP (?) AMA-M2 (?)ANA+ 1/1280 (AC-1 homogeneous) br / AMA (?) LKM (?) ASMA (?) M2-3E (?) Sp-100 (?) gp-210 (?) LKM1 (?) LC1 (?) SLA/LP (?) AMA-M2 (?)ANA+ 1/160 (AC-4 great granular) br / ENA+ (SS-A+, Ro-52+, SS-B+) br / AMA (?) LKM (?) ASMA (?) M2-3E (?) Sp-100 (?) gp-210 (?) LKM1 LDN-212854 (?) LC1 (?) SLA/LP (?) AMA-M2 (?)ANA+ 1/320 (AC-1 homogeneous) br / AMA (?) LKM (?) ASMA (?) M2-3E (?) PHF9 Sp-100 (?) gp-210 (?) LKM1 (?) LC1 (?) SLA/LP (?).